Core Viewpoint - The article highlights the recent financing round completed by Huanying Medical, which will enhance its research and market expansion in ultrasound technology, particularly in interventional imaging, high-frequency imaging, ultrasound liquid transfer, and ultrasound therapy. Group 1: Company Overview - Huanying Medical was established in 2020 and is headquartered in Shenzhen, being incubated by the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences [2] - The company has built three major bases for research and development, pilot testing, and production focused on cutting-edge biomedical ultrasound technology [2] - As a platform company specializing in ultrasound technology, Huanying Medical leverages proprietary technologies in ultrasound transducer, active interventional catheter, and high-frequency ultrasound imaging systems [2] Group 2: Products and Technologies - Huanying Medical has successfully developed high-resolution color ultrasound, intracardiac ultrasound catheters, and non-contact ultrasound liquid transfer devices and consumables [3] - The company possesses proprietary technologies in ultrasound transducer, active interventional catheter, and high-frequency ultrasound imaging systems [3] - Huanying Medical has overcome key technical challenges in 4D-ICE, providing a cost-effective 4D intracardiac imaging solution for global users [3] Group 3: Recent Developments - On May 12, 2025, Huanying Medical announced the completion of a new financing round, led by Nanshan Venture Capital, with participation from existing shareholder Shanghai KET Investment Co., Ltd. [1] - The amount of the financing was not disclosed, and HaoYue Capital served as the exclusive financial advisor for this round [1] - The financing will support Huanying Medical in advancing its research and market expansion in various ultrasound technology fields [1]